Syndesi Therapeutics
Chemin Du Cyclotron 6
1348 Ottignies-Louvain-La-Neuve
BE
Syndesi Therapeutics
Foundation date
19/12/2017
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment.
Upcoming events
All events-
2809 '22
NLSDays 2022
Event by: SwedenBIO -
2405 '22
PrecisionMed Expo & Summit
Event by: Smart Planet Media International -
2405 '22
EMERGE GHI
Event by: Smart Planet Media International
Latest news
More news-
Latest field trials validate strength of Biotalys’ first biocontrol Evoca
Thursday May 19th 2022
Read more
-
Belgian biotech in European Top-3 despite turbulent times
Wednesday May 18th 2022
Read more
-
KU Leuven announces collaboration and license agreement with Gilead Sciences for the development of new antivirals against the respiratory syncytial virus
Wednesday May 18th 2022
Read more